Functional titanium dioxide nanoparticle conjugated with phthalocyanine and folic acid as a promising photosensitizer for targeted photodynamic therapy in vitro and in vivo

Functional titanium dioxide nanoparticle conjugated with phthalocyanine and folic acid as a promising photosensitizer for targeted photodynamic therapy in vitro and in vivo
复制标题

与酞菁和叶酸缀合的功能性二氧化钛纳米颗粒作为一种有前景的光敏剂用于体外和体内靶向光动力治疗

DOI:
10.1016/j.jphotobiol.2020.112122
复制
发表时间:
2021-01-09
影响因子:
5.4
通讯作者:
Mi, Lan
Mi, Lan
中科院分区:
生物学2区
文献类型:
--
作者:
Liang, Xinyue;Xie, Yonghui;Mi, Lan

文献摘要

被引文献

相似文献

光动力疗法(PDT)是一种有前途的癌症治疗方法,可以使用各种药剂来实施。传统的光敏剂Al(III)酞菁氯化物四磺酸(Pc)具有肿瘤靶向选择性、对癌细胞的低亲和力和低双光子吸收的局限性。本研究提出了一种新型的光敏剂FA-TiO 2-Pc,其具有与肿瘤靶向剂叶酸(FA)和Pc缀合的TiO 2纳米颗粒。FA-TiO 2-Pc具有良好的靶向光动力治疗活性和生物相容性。这种有前途的光敏剂在单光子激发(OPE)下在低浓度剂量和短孵育时间下显示出高的治疗药物效率。在体内,当用低剂量的FA-TiO 2-Pc和弱光照射处理时,荷HeLa异种移植瘤的小鼠的肿瘤生长被抑制,副作用最小。此外,FA-TiO 2-Pc的双光子吸收也比Pc有所增强,证明FA-TiO 2-Pc体系在OPE-PDT和双光子激发(TPE)-PDT药物中具有用于治疗叶酸受体阳性癌细胞的巨大潜力。
Photodynamic therapy (PDT) is a promising cancer treatment that can be implemented using various agents. The conventional photosensitizer Al (III) phthalocyanine chloride tetrasulfonic acid (Pc) has limitations of selectivity in tumor targeting, low affinity to cancer cells, and low two-photon absorption. This study presents a novel photosensitizer FA-TiO2-Pc, which has the TiO2 nanoparticle conjugated with a tumor targeting agent of folic acid (FA), and Pc. FA-TiO2-Pc possessed high targeted photodynamic therapeutic activity and excellent biocompatibility. This promising photosensitizer showed high therapeutic drug efficiency in vitro at a low concentration dose and short incubation time under one-photon excitation (OPE). In vivo, when treated with a low dose of FA-TiO2-Pc and low light irradiation, the tumor growth was depressed in mice bearing HeLa xenograft tumors with minimal side effects. In addition, the two-photon absorption of FA-TiO2-Pc was also enhanced compared to Pc, proving that FA-TiO2-Pc system has a great potential to be used for the therapy of the folate receptor positive cancer cells in both OPE-PDT and two-photon excitation (TPE)-PDT agents.